Excellamol

What Excellamol does

Excellamol is a South Korean pre-revenue biopharmaceutical company founded in August 2020 and headquartered in Daegu. The company develops precision oncology therapeutics through its proprietary Self-Depot™ OncoPDC (Oncology Polypeptide-Drug Conjugates) platform, which integrates self-assembling intrinsically disordered polypeptides, tumor-targeting ligands (IL13Rα2, IL4Rα, PD-L1), and highly potent cytotoxic payloads (Exatecan, SN38) to enable image-guided delivery and multi-week local drug retention in hard-to-reach solid tumors. Excellamol targets high-mortality, difficult-to-treat cancers — primarily malignant glioma (including glioblastoma and pediatric diffuse midline glioma) and pancreatic ductal adenocarcinoma — where existing therapeutic options are severely limited.

The company's pipeline comprises five FDA Orphan Drug Designated candidates: XM147-SN38, XM161-SN38, XM182-MVCP-Exatecan, and XM199-MVCP-Exatecan for malignant glioma, plus a PD-L1-targeting OncoPDC for pancreatic cancer. Preclinical data demonstrate sustained intracranial exposure, near complete tumor eradication with prolonged survival in malignant glioma models, minimal systemic exposure, and a favorable neurotoxicity profile. The platform is protected by a global IP estate with granted and pending patents across major international jurisdictions and has been validated through peer-reviewed publications in Neuro-Oncology Advances and presentations at the Society for Neuro-Oncology (SNO) conferences. The company has completed three FDA INTERACT meetings to align on IND-enabling development strategy.

Excellamol's business model is pre-revenue drug development. Future revenue is expected from commercialization of approved therapeutics, distributed through specialty pharmacies and healthcare systems via prescription and reimbursement channels. Current go-to-market is clinical-trial-driven: the company collaborates with Asan Medical Center on pancreatic cancer studies and UCSF Helen Diller Family Comprehensive Cancer Center as a candidate site for first-in-human malignant glioma trials, supported by CMC and GMP manufacturing partnerships with Sterling Pharma Solutions and KBI Biopharma. The company is currently conducting GLP toxicology, pharmacokinetic, and CMC activities in preparation for first-in-human clinical trials planned for 2028.

Name

Excellamol

Legal name

Excellamol

Website

https://excellamol.com

Company type

Private

Founded year

2020

Operating status

Operating

Short description

Excellamol is a South Korean pre-revenue biopharmaceutical company developing Self-Depot™ OncoPDC polypeptide-drug conjugates targeting malignant glioma and pancreatic cancer, with five FDA Orphan Drug Designations and first-in-human trials planned for 2028.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

Keywords

• Polypeptide-drug conjugates
• Oncology therapeutics
• Cancer drug delivery
• Biopharmaceutical R&D
• Targeted cancer therapy

Headquarters

HQ city

Daegu

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Therapeutic Drug Development: Pre-revenue biopharmaceutical company developing novel polypeptide-drug conjugate therapeutics for cancer treatment. Revenue will be generated through drug commercialization upon regulatory approval, likely via prescription through healthcare systems and specialty pharmacies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Excellamol develops precision cancer therapeutics using its proprietary Self-Depot™ OncoPDC (Oncology Polypeptide-Drug Conjugates) platform. The platform integrates self-assembling polypeptides, tumor-targeting ligands, and potent cytotoxic payloads (Exatecan, SN38) to enable image-guided precision delivery and sustained local retention in difficult-to-treat solid tumors, with current focus on malignant glioma and pancreatic cancer. The company is pre-revenue, advancing five OncoPDC pipeline candidates through FDA regulatory pathways toward first-in-human clinical trials planned for 2028.

Product overview

Excellamol offers a unified Self-Depot™ OncoPDC platform for developing polypeptide-drug conjugate therapeutics. The platform enables targeted delivery of cytotoxic or immune-modulating payloads into hard-to-reach solid tumors, particularly brain and pancreatic cancers. Five OncoPDC pipeline candidates are in development: XM182-MVCP-Exatecan (IL13Rα2-targeting), XM199-MVCP-Exatecan (IL4Rα-targeting), XM147-SN38, XM161-SN38, and a PD-L1-targeting OncoPDC, all targeting high-mortality cancers with limited therapeutic options.

Differentiator

Problem solved

Functional benefit

Brands

• Self-Depot™ OncoPDC: Precision therapeutics delivery technology platform engineered to achieve sustained local retention, prolonged tumor exposure, and minimal systemic leakage in difficult-to-penetrate solid tumors.

Products and services

• Self-Depot™ OncoPDC Platform Proprietary precision therapeutics delivery platform integrating self-assembling polypeptides, tumor-targeting ligands, and highly potent anticancer payloads to enable sustained intracranial and local drug retention following a single administration in hard-to-reach solid tumors.
• XM182-MVCP-Exatecan (IL13Rα2-targeting OncoPDC) An OncoPDC therapeutic candidate targeting the IL13Rα2 receptor, granted FDA Orphan Drug Designation for malignant glioma treatment. Combines self-assembling polypeptide backbone with Exatecan cytotoxic payload.
• XM199-MVCP-Exatecan (IL4Rα-targeting OncoPDC) An OncoPDC therapeutic candidate targeting the IL4Rα receptor, granted FDA Orphan Drug Designation for malignant glioma treatment, combining self-assembling polypeptide technology with Exatecan payload.
• XM147-SN38 An OncoPDC therapeutic candidate combining self-assembling polypeptide carrier with SN38 cytotoxic payload, granted FDA Orphan Drug Designation for malignant glioma treatment.
• XM161-SN38 An FDA Orphan Drug Designated OncoPDC therapy using SN38 payload for brain cancers including glioblastoma, presented at the BTR-NTA program engaging with leading brain tumor experts.
• PD-L1-targeting OncoPDC (Pancreatic Cancer) A PD-L1-targeting OncoPDC therapeutic candidate granted FDA Orphan Drug Designation for pancreatic cancer treatment, designed to enhance tumor-selective drug accumulation while minimizing systemic exposure.

Quantifiable outcome

• Near complete eradication with prolonged survival in malignant glioma models
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Sterling Pharma SolutionscoreStrategic or Co-development PartnerCollaboration for CMC development and GMP manufacturing of OncoPDC therapeutics. Sterling Pharma Solutions provides contract development and manufacturing organization (CDMO) services supporting IND-enabling studies and clinical supply for Excellamol's pipeline programs.
• KBI BiopharmacoreStrategic or Co-development PartnerCollaboration for CMC development and GMP manufacturing of OncoPDC therapeutics. KBI Biopharma provides biopharmaceutical development and manufacturing services supporting Excellamol's GLP toxicokinetics and safety pharmacology programs.
• Asan Medical CentercoreStrategic or Co-development PartnerClinical development collaboration for pancreatic cancer clinical studies. Asan Medical Center, a leading Korean medical institution, serves as a clinical trial site and development partner for Excellamol's pancreatic cancer OncoPDC program.
• UCSF Helen Diller Family Comprehensive Cancer CentercoreStrategic or Co-development PartnerCandidate site for first-in-human malignant glioma clinical trials. UCSF, a leading US academic medical center, is being evaluated as a clinical trial site for Excellamol's lead GBM OncoPDC candidate.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mersana Therapeutics: Clinical-stage developer of antibody-drug conjugates (ADCs) and other targeted cytotoxic conjugates for oncology, including Dolasynthen and Immunosynthen platforms. Excellamol's OncoPDC platform applies the same targeting-ligand-plus-cytotoxic-payload concept with polypeptides instead of antibodies, positioning Mersana as a direct mechanistic comparator.
• CytomX Therapeutics: Develops Probody drug conjugates — masked antibody-drug conjugates designed to localize payload activity in the tumor microenvironment. Excellamol's tumor-localized self-depotting polypeptides share CytomX's goal of confining cytotoxic exposure to tumor tissue, making it a directly comparable targeted-conjugate developer.
• Tubulis: Develops next-generation ADCs with a focus on novel linker chemistry and stable conjugation strategies for solid tumor oncology. Both Tubulis and Excellamol are building differentiated payload-conjugate platforms aimed at improving therapeutic index in solid tumor indications.
• Pyxis Oncology: Clinical-stage ADC and immuno-oncology developer with pipeline programs targeting solid tumors. As a developer of novel targeted cytotoxic conjugates, Pyxis represents a directly comparable peer in modality, indication (solid tumors), and stage of development.
• Bolt Biotherapeutics: Developer of immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune-activating payloads. Shares Excellamol's architecture of a targeting ligand conjugated to a potent payload, though Bolt uses immune-modulating payloads rather than cytotoxics.
• ADC Therapeutics: Clinical and commercial-stage ADC developer (ZYNLONTA, loncastuximab tesirine) with a pipeline of targeted cytotoxic conjugates for hematologic and solid tumors. The most mature pure-play ADC peer, providing a benchmark for clinical translation, regulatory pathway, and commercial execution.
• Molecular Templates: Developer of engineered toxin bodies (ETBs) — targeted, genetically engineered protein scaffolds delivering cytotoxic payloads to tumors. Shares Excellamol's approach of using non-antibody protein scaffolds as targeting ligands for cytotoxic payloads in oncology.
• ProfoundBio: Clinical-stage developer of next-generation ADCs with proprietary linker and payload chemistry, focused on solid tumors including ovarian and other difficult-to-treat cancers. Comparable as a peptide-/antibody-based targeted conjugate developer in oncology.
• Ziopharm Oncology (now Alaunos Therapeutics): Pursues IL13Rα2-targeted approaches for glioblastoma — the same receptor target as Excellamol's XM182-MVCP-Exatecan. Direct indication and target overlap make this a critical competitive peer in Excellamol's lead GBM program.
• Kazia Therapeutics: Clinical-stage oncology company developing therapies for brain cancer, including paxalisib for glioblastoma. Directly comparable as a focused GBM therapeutics developer with a similar stage and indication profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Excellamol